Neoc Bio adapts its dual-targeting ADC strategy based on the antigen profile. For tumor-specific antigens, an "OR-gated" design enhances efficacy by binding if either target is present. For antigens also found on healthy cells, an "AND-gated" design improves safety by requiring both targets to be present for binding, thus sparing healthy tissue.
The ADC field faces a future challenge: as TOPA1 payload-based ADCs become standard treatments, patients will develop resistance. This will render other TOPA1-based ADCs ineffective for those patients, creating a significant market need and R&D focus on developing entirely new classes of therapeutic payloads to overcome this mechanism.
Neoc Bio's structure is a strategic play to bridge biotech ecosystems. It leverages the bispecific antibody R&D engine and initial funding from its Korean parent, ABL Bio, to establish a US-based entity. This model is designed specifically to attract US investors, talent, and capital markets to accelerate the development of its ADC pipeline.
Neoc Bio is conducting its Phase 1 trials exclusively in the United States. The CEO identifies this as a strategic choice, believing that generating clinical data solely from the US will be viewed more favorably by American investors, regulators, and potential partners, positioning the company for future financing and development success.